Pharvaris Holds €292M Cash, On Track for 1H2026 NDA and Q3 2026 Data
Pharvaris completed enrollment in its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR for prophylactic HAE treatment, with topline data expected in 3Q2026 and NDA submission of deucrictibant IR on schedule for 1H2026. Cash and cash equivalents rose to €292 million at December 31, 2025, supporting ongoing trials.
1. Clinical Trial Progress
Enrollment is complete in the pivotal CHAPTER-3 Phase 3 study of orally administered deucrictibant XR (40 mg) for prophylactic treatment of HAE attacks in adults and adolescents, with topline data anticipated in the third quarter of 2026. Enrollment continues in CHAPTER-4, an open-label extension of deucrictibant XR prophylaxis, and in CREAATE, a global pivotal study evaluating both prophylactic XR and on-demand IR formulations for acquired angioedema due to C1 inhibitor deficiency.
2. RAPIDe-3 Efficacy Data
The RAPIDe-3 pivotal study met its primary and all 11 secondary endpoints, demonstrating a median onset of symptom relief in 1.28 hours and complete resolution in 11.95 hours with deucrictibant IR versus placebo. These results support its differentiated profile for on-demand HAE treatment and form the basis of the planned first-half 2026 NDA submission.
3. Financial Position
Pharvaris reported cash and cash equivalents of €292 million at December 31, 2025, up from €281 million a year earlier, providing runway to fund ongoing Phase 3 trials and support the anticipated NDA submission and data readouts through 2026.